Allogeneic stem-cell transplantation for renal-cell cancer

Lancet Oncology

Volumn 5, Issue 9, 2004, Pages 561-567

  Gommersall, Lyndon ^a   Hayne, Dickon ^a   Lynch, Ciaran ^b   Joseph, Jean V ^d   Arya, Manit ^c   Patel, Hitendra R H ^d,e,f  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; FLUDARABINE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MELPHALAN; MESSENGER RNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; BACTERIAL INFECTION; BONE MARROW; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CHIMERA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER VENOOCCLUSIVE DISEASE; METASTASIS; MYCOSIS; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SOLID TUMOR; VIRUS INFECTION;

AGED; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 4444307149     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01568-2     Document Type: Review

References (52)

1. Cancer Research UK. Statistics. http://www.cruk.co.uk/aboutcancer/statistics/incidence (accessed August, 2004)
2. British Association of Urological Surgeons, Section of Oncology. Analysis of minimum dataset for urological cancers, 2001. London: British Association of Urological Surgeons, 2002: 45.
3. Quinn M.J. Babb P. Brock A. et al. Cancer trends in England and Wales 1950-1999. Studies in medical and population subjects, series 66. London: Stationery Office, 2001.
4. Motzer RJ Mazumdar M Bacik J et al. Effect of cytokine therapy on survival for patients with advanced renal-cell carcinoma J Clin Oncol 18 2000 1928-1935
5. Neumann E Engelsberg A Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal-cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58 1998 4090-4095
6. Liao SY Aurelio ON Jan K et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney Cancer Res 57 1997 2827-2831
7. Vissers JL De Vries IJ Schreurs MW et al. The renal-cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes Cancer Res 59 1999 5554-5559
8. Oosterwijk-Wakka JC Tiemessen DM Bleumer I et al. Vaccination of patients with metastatic renal-cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study J Immunother 25 2002 500-508
9. Jayson M Sanders H. Increased incidence of serendipitously discovered renal-cell carcinoma Urology 51 1998 203-205
10. Kavolius JP Mastorakos DP Pavlovich C et al. Resection of metastatic renal-cell carcinoma J Clin Oncol 16 1998 2261-2266
11. Flanigan RC Salmon SE Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655-1659
12. Yagoda A Abi-Rached B Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993 Semin Oncol 22 1995 42-60
13. Rini BI Vogelzang NJ Dumas MC et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer J Clin Oncol 18 2000 2419-2426
14. Motzer RJ Russo P. Systemic therapy for renal-cell carcinoma J Urol 163 2000 408-417
15. Rosenberg SA Yang JC Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 1994 907-913
16. Yang JC Sherry RM Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 2003 3127-3132
17. Biron CA Nguyen KB Pien GC et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines Annu Rev Immunol 17 1999 189-220
18. Hancock BW Harris S Wheatley K Gore M. Adjuvant interferon-alpha in malignant melanoma: current status Cancer Treat Rev 26 2000 81-89
19. Coppin C. Porzsolt F. Kumpf J. et al. Immunotherapy for advanced renal cell cancer (Cochrane Review). In: Cochrane Library, Issue 3, 2000: CD001425.
20. Rosenberg SA Yannelli JR Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 86 1994 1159-1166
21. Rosenberg SA. Progress in human tumour immunology and immunotherapy Nature 411 2001 380-384
22. Heiser A Maurice MA Yancey DR et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors Cancer Res 61 2001 3388-3393
23. Su Z Dannull J Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells Cancer Res 63 2003 2127-2133
24. Hanahan D Weinberg RA. The hallmarks of cancer Cell 100 2000 57-70
25. Lahn M Fisch P Kohler G et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal-cell carcinoma Eur Urol 35 1999 70-80
26. Troy AJ Summers KL Davidson PJ et al. Minimal recruitment and activation of dendritic cells within renal-cell carcinoma Clin Cancer Res 4 1998 585-593
27. Seliger B Hohne A Knuth A et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal-cell carcinomas with low TAP and LMP expression Clin Cancer Res 2 1996 1427-1433
28. Kallfelz M Jung D Hilmes C et al. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer Int J Cancer 81 1999 125-133
29. Uzzo RG Clark PE Rayman P et al. Alterations in NFkappaB activation in T lymphocytes of patients with renal-cell carcinoma J Natl Cancer Inst 91 1999 718-721
30. Ling W Rayman P Uzzo R et al. Impaired activation of NFkappaB in T cells from a subset of renal-cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha Blood 92 1998 1334-1341
31. Oyama T Ran S Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells J Immunol 160 1998 1224-1232
32. Tabbara IA Zimmerman K Morgan C Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results Arch Intern Med 162 2002 1558-1566
33. McDonald GB Hinds MS Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 118 1993 255-267
34. Blaise D Bay JO Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors Blood 103 2004 435-441
35. Bregni M Dodero A Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234-4236
36. Ueno NT Cheng YC Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood 102 2003 3829-3836
37. Hentschke P Barkholt L Uzunel M et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma Bone Marrow Transplant 31 2003 253-261
38. Baron F Frere P Baudoux E et al. Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal-cell carcinoma Haematologica 88 2003 479-480
39. Pedrazzoli P Da Prada GA Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies Cancer 94 2002 2409-2415
40. Giralt S Estey E Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531-4536
41. Slavin S Nagler A Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
42. Childs R Drachenberg D. Allogeneic stem cell transplantation for renal-cell carcinoma Curr Opin Urol 11 2001 495-502
43. Porter DL Connors JM Van Deerlin VM et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies J Clin Oncol 17 1999 1234
44. Rini BI Zimmerman T Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results J Clin Oncol 20 2002 2017-2024
45. Childs RW Clave E Tisdale J et al. Successful treatment of metastatic renal-cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect J Clin Oncol 17 1999 2044-2049
46. Childs R Chernoff A Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med 343 2000 750-758
47. Mena O.J. Carvello C. Drachenberg D.E. et al. J Urol 2002; 167 (suppl): 123.
48. Helg C Starobinski M Jeannet M Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation Leuk Lymphoma 29 1998 301-313
49. Marmont AM. Alloimmune effects of bone marrow transplantation for leukaemia on the leukaemic diseases Bone Marrow Transplant 7 suppl 2 1991 2-3
50. Nimer SD Giorgi J Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomised controlled trial Transplantation 57 1994 82-87
51. Storb R.F. Lucarelli G. McSweeney P.A. Childs R.W. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology (Am Soc Hematol Educ Program) 2003; 372-97.
52. Childs R Barrett J. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy Semin Hematol 39 2002 63-71